In our study, users of ATr blockers had a smaller proportion of metastatic cancer cases, a lower likelihood of initiation of ADT therapy, and lower PCa mortality as compared to patients in the other groups. The gene discussed is ATR; the disease is metastatic malignant neoplasm.